Pacira Biosciences Inc PCRX:NASDAQ

Last Price$39.87Cboe Previous Close - Real-Time Last Sale as of 3:59PM ET 7/19/19
Cboe Real-Time Quotes
Today's Change0(0.00%)
Bid (Size)$39.36 (100)
Ask (Size)$40.40 (100)
Day Low / HighN/A - N/A
Volume340.3 K

Pacira Pharmaceuticals Reports Efficacy & Safety of Treatment for Patients Undergoing Shoulder Arthroplasty

8:15AM ET 6/04/2019 MT Newswires
Pacira Pharmaceuticals (PCRX) said a multinational phase 3 study supported the efficacy and safety of exparel as a single-injection interscalene brachial plexus nerve block (ISNB) in patients undergoing total shoulder arthroplasty or rotator cuff repair.

The company said the results demonstrated exparel "significantly improved pain control and reduced opioid consumption" through 48 hours compared with placebo and a "standardized" pain management protocol alone.

A total of 140 patients enrolled across 16 surgical centers in the US, Belgium, and Denmark were randomized to receive an ultrasound-guided single-dose ISNB with either exparel 133 mg (n=69) or saline placebo (n=71).

"Results from this study illustrate the clinical effectiveness of an interscalene brachial plexus nerve block with exparel, which provides prolonged pain control in a single dose without the need for additional equipment," said Manish Patel, an investigator in the study.

Price: 42.52, Change: -0.99, Percent Change: -2.28